Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
OPERATING EXPENSES
Research and development expenses	$ 28,346	$ 23,197
General and administrative expenses	412,062	503,405
Total operating expenses	440,408	526,602
LOSS FROM OPERATIONS	(440,408)	(526,602)
LOSS, BEFORE TAX	(440,408)	(526,602)
Income tax benefit (expense)
NET LOSS	$ (440,408)	$ (526,602)
Net loss per share attributable to common stockholders, basic	$ (0.03)	$ (0.05)
Net loss per share attributable to common stockholders, diluted	$ (0.03)	$ (0.05)
Weighted average common shares outstanding used in computing net loss per share attributable to common stockholders, basic	12,723,721	11,346,535
Weighted average common shares outstanding used in computing net loss per share attributable to common stockholders, diluted	12,723,721	11,346,535
NET LOSS	$ (440,408)	$ (526,602)